Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


How to respond when the grand vision becomes a cold reality

22 November 2013

New ventures are started for many reasons, with one of the most common routes beginning with someone doing a job they like in a big company and thinking they want to do it for themselves, but where do they go from there, asks Timothy Barnes, Director of UCL Enterprise Operations and UCL Advances.

Read the full article at thetimes.co.uk